-
Je něco špatně v tomto záznamu ?
Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update
D. Aletaha, A. Kerschbaumer, K. Kastrati, C. Dejaco, M. Dougados, IB. McInnes, N. Sattar, TA. Stamm, T. Takeuchi, M. Trauner, D. van der Heijde, M. Voshaar, KL. Winthrop, A. Ravelli, N. Betteridge, GR. Burmester, JW. Bijlsma, V. Bykerk, R....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu konsensus - konference, časopisecké články, práce podpořená grantem
Grantová podpora
G1001518
Medical Research Council - United Kingdom
NLK
ProQuest Central
od 1939-01-01 do Před 6 měsíci
Health & Medicine (ProQuest)
od 1939-01-01 do Před 6 měsíci
Family Health Database (ProQuest)
od 1939-01-01 do Před 6 měsíci
ROAD: Directory of Open Access Scholarly Resources
PubMed
35953263
DOI
10.1136/ard-2022-222784
Knihovny.cz E-zdroje
- MeSH
- COVID-19 MeSH
- dospělí MeSH
- interleukin-6 MeSH
- lidé MeSH
- receptory interleukinu-6 * antagonisté a inhibitory MeSH
- revmatoidní artritida farmakoterapie MeSH
- Stillova nemoc dospělých farmakoterapie MeSH
- zánět * farmakoterapie MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- konsensus - konference MeSH
- práce podpořená grantem MeSH
BACKGROUND: Targeting interleukin (IL)-6 has become a major therapeutic strategy in the treatment of immune-mediated inflammatory disease. Interference with the IL-6 pathway can be directed at the specific receptor using anti-IL-6Rα antibodies or by directly inhibiting the IL-6 cytokine. This paper is an update of a previous consensus document, based on most recent evidence and expert opinion, that aims to inform on the medical use of interfering with the IL-6 pathway. METHODS: A systematic literature research was performed that focused on IL-6-pathway inhibitors in inflammatory diseases. Evidence was put in context by a large group of international experts and patients in a subsequent consensus process. All were involved in formulating the consensus statements, and in the preparation of this document. RESULTS: The consensus process covered relevant aspects of dosing and populations for different indications of IL-6 pathway inhibitors that are approved across the world, including rheumatoid arthritis, polyarticular-course and systemic juvenile idiopathic arthritis, giant cell arteritis, Takayasu arteritis, adult-onset Still's disease, Castleman's disease, chimeric antigen receptor-T-cell-induced cytokine release syndrome, neuromyelitis optica spectrum disorder and severe COVID-19. Also addressed were other clinical aspects of the use of IL-6 pathway inhibitors, including pretreatment screening, safety, contraindications and monitoring. CONCLUSIONS: The document provides a comprehensive consensus on the use of IL-6 inhibition to treat inflammatory disorders to inform healthcare professionals (including researchers), patients, administrators and payers.
Department of Clinical Medicine Copenhagen University Hospital Kobenhavn Denmark
Department of Clinical Medicine University of Copenhagen Kobenhavn Denmark
Department of Clinical Sciences and Community Health ASS G Pini University of Milan Milano Italy
Division of Gastroenterology and Hepatology Medical University of Vienna Wien Austria
Division of Rheumatology Geneva University Hospitals Geneve Switzerland
Division of Rheumatology Kantonsspital Sankt Gallen Sankt Gallen Switzerland
Division of Rheumatology Medical University of Vienna Wien Austria
Forschungsbereich Epidemiologie Deutsches Rheuma Forschungszentrum Berlin Berlin Germany
Griffith University School of Medicine Gold Coast Queensland Australia
Immunorhumatologie CHU Lapeyronie Montpellier France
Institute of Infection Immunity and Inflammation University of Glasgow Glasgow UK
Leeds Teaching Hospitals NHS Trust NIHR Leeds Musculoskeletal Biomedical Research Unit Leeds UK
Mary Kirkland Center for Lupus Research Hospital for Special Surgery New York City New York USA
Medical Humanities Amsterdam University Medical Centres Duivendrecht The Netherlands
Medicine Rheumatology Albany Medical College Albany New York USA
Medicine The University of Texas Southwestern Medical Center Dallas Texas USA
National Institute of Rheumatology and Physiology Semmelweis University Budapest Hungary
Neil Betteridge Associates Limited London UK
Organización Médica de Investigación SA Buenos Aires Argentina
Rheumatology Amsterdam UMC Locatie VUmc Amsterdam The Netherlands
Rheumatology and Clinical Immunology Charite University Hospital Berlin Berlin Germany
Rheumatology Assistance Publique Hôpitaux de Paris Paris France
Rheumatology Brunico Hospital Brunico Italy
Rheumatology Carol Davila University of Medicine and Pharmacy Bucuresti Romania
Rheumatology Department Charles University Praha Czech Republic
Rheumatology Diakonhjemmet Hospital Oslo Norway
Rheumatology Leiden University Medical Center Leiden The Netherlands
Rheumatology Medical University of Graz Graz Austria
Rheumatology Universite Paris Descartes Faculte de Medecine Site Cochin Paris France
Rheumatology University of Pennsylvania Philadelphia Pennsylvania USA
Rheumatology University of Toronto Toronto Ontario Canada
Scienze Cliniche e Biologiche Università degli Studi di Torino Torino Italy
Section for Outcomes Research Medical University of Vienna Wien Austria
Translational and Clinical Research Institute Newcastle University Newcastle upon Tyne UK
University of Leeds Leeds Institute of Rheumatic and Musculoskeletal Medicine Leeds UK
UO Pediatria 2 Reumatologia IRCCS Istituto Giannina Gaslini Genova Italy
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23011330
- 003
- CZ-PrNML
- 005
- 20230801132954.0
- 007
- ta
- 008
- 230718s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1136/ard-2022-222784 $2 doi
- 035 __
- $a (PubMed)35953263
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Aletaha, Daniel $u Division of Rheumatology, Medical University of Vienna, Wien, Austria daniel.aletaha@meduniwien.ac.at $1 https://orcid.org/0000000321080030
- 245 10
- $a Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update / $c D. Aletaha, A. Kerschbaumer, K. Kastrati, C. Dejaco, M. Dougados, IB. McInnes, N. Sattar, TA. Stamm, T. Takeuchi, M. Trauner, D. van der Heijde, M. Voshaar, KL. Winthrop, A. Ravelli, N. Betteridge, GR. Burmester, JW. Bijlsma, V. Bykerk, R. Caporali, EH. Choy, C. Codreanu, B. Combe, MK. Crow, M. de Wit, P. Emery, RM. Fleischmann, C. Gabay, ML. Hetland, KL. Hyrich, A. Iagnocco, JD. Isaacs, JM. Kremer, X. Mariette, PA. Merkel, EF. Mysler, P. Nash, MT. Nurmohamed, K. Pavelka, G. Poor, A. Rubbert-Roth, H. Schulze-Koops, A. Strangfeld, Y. Tanaka, JS. Smolen
- 520 9_
- $a BACKGROUND: Targeting interleukin (IL)-6 has become a major therapeutic strategy in the treatment of immune-mediated inflammatory disease. Interference with the IL-6 pathway can be directed at the specific receptor using anti-IL-6Rα antibodies or by directly inhibiting the IL-6 cytokine. This paper is an update of a previous consensus document, based on most recent evidence and expert opinion, that aims to inform on the medical use of interfering with the IL-6 pathway. METHODS: A systematic literature research was performed that focused on IL-6-pathway inhibitors in inflammatory diseases. Evidence was put in context by a large group of international experts and patients in a subsequent consensus process. All were involved in formulating the consensus statements, and in the preparation of this document. RESULTS: The consensus process covered relevant aspects of dosing and populations for different indications of IL-6 pathway inhibitors that are approved across the world, including rheumatoid arthritis, polyarticular-course and systemic juvenile idiopathic arthritis, giant cell arteritis, Takayasu arteritis, adult-onset Still's disease, Castleman's disease, chimeric antigen receptor-T-cell-induced cytokine release syndrome, neuromyelitis optica spectrum disorder and severe COVID-19. Also addressed were other clinical aspects of the use of IL-6 pathway inhibitors, including pretreatment screening, safety, contraindications and monitoring. CONCLUSIONS: The document provides a comprehensive consensus on the use of IL-6 inhibition to treat inflammatory disorders to inform healthcare professionals (including researchers), patients, administrators and payers.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a revmatoidní artritida $x farmakoterapie $7 D001172
- 650 _2
- $a COVID-19 $7 D000086382
- 650 _2
- $a interleukin-6 $7 D015850
- 650 12
- $a receptory interleukinu-6 $x antagonisté a inhibitory $7 D019947
- 650 _2
- $a Stillova nemoc dospělých $x farmakoterapie $7 D016706
- 650 12
- $a zánět $x farmakoterapie $7 D007249
- 655 _2
- $a konsensus - konference $7 D016446
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Kerschbaumer, Andreas $u Division of Rheumatology, Medical University of Vienna, Wien, Austria $1 https://orcid.org/0000000266858873
- 700 1_
- $a Kastrati, Kastriot $u Division of Rheumatology, Medical University of Vienna, Wien, Austria
- 700 1_
- $a Dejaco, Christian $u Rheumatology, Medical University of Graz, Graz, Austria $u Rheumatology, Brunico Hospital, Brunico, Italy $1 https://orcid.org/0000000201730668
- 700 1_
- $a Dougados, Maxime $u Rheumatology, Universite Paris Descartes Faculte de Medecine Site Cochin, Paris, France $1 https://orcid.org/0000000330096229
- 700 1_
- $a McInnes, Iain B $u Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK
- 700 1_
- $a Sattar, Naveed $u Institute of Cardiovascular and Medical Sciences, British Heart Foundation Glasgow Cardiovascular Research Centre, Glasgow, UK
- 700 1_
- $a Stamm, Tanja A $u Section for Outcomes Research, Medical University of Vienna, Wien, Austria $1 https://orcid.org/0000000330737284
- 700 1_
- $a Takeuchi, Tsutomu $u Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine Graduate School of Medicine, Shinjuku-ku, Japan $1 https://orcid.org/0000000311118218
- 700 1_
- $a Trauner, Michael $u Division of Gastroenterology and Hepatology, Medical University of Vienna, Wien, Austria
- 700 1_
- $a van der Heijde, Désirée $u Rheumatology, Leiden University Medical Center, Leiden, The Netherlands $u Rheumatology, Diakonhjemmet Hospital, Oslo, Norway $1 https://orcid.org/000000025781158X
- 700 1_
- $a Voshaar, Marieke $u Department of Psychology, Health and Technology, Enschede, Netherlands and Stichting Tools Patient Empowerment, University of Twente, Enschede, The Netherlands
- 700 1_
- $a Winthrop, Kevin L $u Schools of Medicine and Public Health, Division of Infectious Diseases, Oregon Health & Science University, Portland, Oregon, USA $1 https://orcid.org/0000000238926947
- 700 1_
- $a Ravelli, Angelo $u UO Pediatria II-Reumatologia, IRCCS Istituto Giannina Gaslini, Genova, Italy $1 https://orcid.org/0000000196580385
- 700 1_
- $a Betteridge, Neil $u Neil Betteridge Associates Limited, London, UK
- 700 1_
- $a Burmester, Gerd-Rüdiger R $u Rheumatology and Clinical Immunology, Charite University Hospital Berlin, Berlin, Germany $1 https://orcid.org/0000000175181131
- 700 1_
- $a Bijlsma, Johannes Wj $u Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands $1 https://orcid.org/0000000201288451
- 700 1_
- $a Bykerk, Vivian $u Rheumatology, University of Toronto, Toronto, Ontario, Canada
- 700 1_
- $a Caporali, Roberto $u Department of Clinical Sciences and Community Health, ASS G. Pini, University of Milan, Milano, Italy
- 700 1_
- $a Choy, Ernest H $u CREATE Centre, Section of Rheumatology, School of Medicine, Division of Infection and Immunity, Cardiff University, Cardiff, UK $1 https://orcid.org/0000000344598609
- 700 1_
- $a Codreanu, Catalin $u Rheumatology, Carol Davila University of Medicine and Pharmacy, Bucuresti, Romania
- 700 1_
- $a Combe, Bernard $u Immunorhumatologie, CHU Lapeyronie, Montpellier, France
- 700 1_
- $a Crow, Mary K $u Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York City, New York, USA $1 https://orcid.org/0000000278812020
- 700 1_
- $a de Wit, Maarten $u Medical Humanities, Amsterdam University Medical Centres, Duivendrecht, The Netherlands $1 https://orcid.org/0000000284286354
- 700 1_
- $a Emery, Paul $u University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK $u Leeds Teaching Hospitals NHS Trust, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK $1 https://orcid.org/0000000274298482
- 700 1_
- $a Fleischmann, Roy M $u Medicine, The University of Texas Southwestern Medical Center, Dallas, Texas, USA $1 https://orcid.org/0000000266301477
- 700 1_
- $a Gabay, Cem $u Division of Rheumatology, Geneva University Hospitals, Geneve, Switzerland
- 700 1_
- $a Hetland, Merete Lund $u Department of Clinical Medicine, Copenhagen University Hospital, Kobenhavn, Denmark $u Department of Clinical Medicine, University of Copenhagen, Kobenhavn, Denmark
- 700 1_
- $a Hyrich, Kimme L $u Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK $1 https://orcid.org/0000000182429262
- 700 1_
- $a Iagnocco, Annamaria $u Scienze Cliniche e Biologiche, Università degli Studi di Torino, Torino, Italy $1 https://orcid.org/000000015592724X
- 700 1_
- $a Isaacs, John D $u Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK $1 https://orcid.org/0000000261037056 $7 xx0256897
- 700 1_
- $a Kremer, Joel M $u Medicine Rheumatology, Albany Medical College, Albany, New York, USA
- 700 1_
- $a Mariette, Xavier $u Rheumatology, Assistance Publique-Hôpitaux de Paris, Paris, France $u Center for Immunology of Viral Infections and Auto-immune Diseases, Université Paris-Sud, Gif-sur-Yvette, France $1 https://orcid.org/0000000242445417
- 700 1_
- $a Merkel, Peter A $u Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA $1 https://orcid.org/0000000192847345
- 700 1_
- $a Mysler, Eduardo F $u Organización Médica de Investigación SA, Buenos Aires, Argentina
- 700 1_
- $a Nash, Peter $u Griffith University School of Medicine, Gold Coast, Queensland, Australia $1 https://orcid.org/000000022571788X
- 700 1_
- $a Nurmohamed, Michael T $u Rheumatology, Amsterdam UMC Locatie VUmc, Amsterdam, The Netherlands $1 https://orcid.org/0000000262741934
- 700 1_
- $a Pavelka, Karel $u Rheumatology Department, Charles University, Praha, Czech Republic
- 700 1_
- $a Poor, Gyula $u National Institute of Rheumatology & Physiology, Semmelweis University, Budapest, Hungary
- 700 1_
- $a Rubbert-Roth, Andrea $u Division of Rheumatology, Kantonsspital Sankt Gallen, Sankt Gallen, Switzerland $1 https://orcid.org/0000000290162833
- 700 1_
- $a Schulze-Koops, Hendrik $u Division of Rheumatology and Clinical Immunology, Internal Medicine IV, Ludwig-Maximilians-Universitat Munchen, Munchen, Germany $1 https://orcid.org/000000021681491X
- 700 1_
- $a Strangfeld, Anja $u Forschungsbereich Epidemiologie, Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany $1 https://orcid.org/000000026233022X
- 700 1_
- $a Tanaka, Yoshiya $u First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan $1 https://orcid.org/0000000208077139
- 700 1_
- $a Smolen, Josef S $u Division of Rheumatology, Medical University of Vienna, Wien, Austria
- 773 0_
- $w MED00000444 $t Annals of the rheumatic diseases $x 1468-2060 $g Roč. 82, č. 6 (2023), s. 773-787
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35953263 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230718 $b ABA008
- 991 __
- $a 20230801132951 $b ABA008
- 999 __
- $a ok $b bmc $g 1963628 $s 1197595
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 82 $c 6 $d 773-787 $e 20220811 $i 1468-2060 $m Annals of the rheumatic diseases $n Ann Rheum Dis $x MED00000444
- GRA __
- $a G1001518 $p Medical Research Council $2 United Kingdom
- LZP __
- $a Pubmed-20230718
